AI-Powered Personalized Cancer Vaccine Saves Dog’s Life, Offers Hope for Human Treatments

In a groundbreaking development, an Australian tech entrepreneur utilized artificial intelligence to design a personalized mRNA cancer vaccine for his dog, Rosie, offering a potential blueprint for future human cancer therapies. The case highlights the rapidly evolving role of AI in veterinary and human medicine.

From Grim Diagnosis to AI-Driven Solution

In 2024, Paul Conyngham, a Sydney-based tech entrepreneur, received the devastating news that his eight-year-old rescue dog, Rosie, had been diagnosed with mast cell cancer. Despite initial treatments including chemotherapy and surgery, the tumors persisted and Rosie’s condition deteriorated. Facing a bleak prognosis, Conyngham, an electrical and computing engineer and co-founder of Core Intelligence Technologies, decided to leverage his expertise and explore alternative solutions.

ChatGPT as a Starting Point

Lacking a medical background, Conyngham turned to OpenAI’s ChatGPT for guidance. He asked the AI how to design a personalized cancer treatment based on the tumor’s genome. ChatGPT served as a crucial tool in structuring his approach, identifying necessary analyses, relevant technologies, and potential researchers to contact. Fortune reports that Conyngham used ChatGPT to create a plan for developing the vaccine.

Genomic Sequencing and AI Analysis

Following ChatGPT’s suggestions, Conyngham contacted the Ramaciotti Center for Genomics at the University of New South Wales (UNSW). For approximately $3,000 AUD, the center sequenced Rosie’s tumor DNA and healthy tissue. Conyngham then analyzed the genomic data, comparing healthy and cancerous cells to pinpoint mutations specific to Rosie’s cancer. He utilized Google’s DeepMind’s AlphaFold, an AI tool, to model the structure of these mutated proteins, identifying potential therapeutic targets. Daily Mail details this process.

Bespoke mRNA Vaccine Development

While a promising immunotherapy treatment was identified, the drugmaker refused to provide it for compassionate use. This led Conyngham to collaborate with Pall Thordarson, director of UNSW’s RNA Institute and a pioneer in nanomedicine. Thordarson used Conyngham’s data to develop a custom mRNA vaccine within two months, designed to train Rosie’s immune system to recognize and attack cells carrying the identified mutations. Yahoo News confirms this collaboration.

Results and Future Implications

According to Conyngham and the researchers, the primary tumor on Rosie’s paw significantly shrank, with improvements in her energy and mobility. While not a complete cure, the treatment demonstrably improved Rosie’s quality of life and potentially extended her lifespan. Thordarson cautioned that the treatment may not have eradicated all tumors, but acknowledged its significant impact. Firstpost highlights the positive impact on Rosie’s well-being.

Thordarson emphasized that this is the first instance of a personalized cancer vaccine designed specifically for a dog. He believes Rosie’s case demonstrates the potential of personalized medicine, particularly with mRNA technology, and could pave the way for more efficient and accessible cancer treatments for both animals and humans. He suggests that genomic analysis and RNA production could become streamlined services with increased automation.

Looking Ahead

Conyngham has launched a Google form to gather information from individuals interested in exploring similar approaches for both human and animal cancers. While Rosie’s story remains an isolated case lacking a formal clinical trial, it represents a compelling proof-of-concept and a promising step forward in the fight against cancer. Further research and rigorous studies are needed to validate these findings and translate them into widespread clinical applications.